GMP Cytokines Market Size, Trends and Growth Analysis by 2027

The GMP cytokines market is projected to grow significantly, reaching an estimated US$ 158.13 million by 2027, up from US$ 84.72 million in 2019. This growth represents a compound annual growth rate (CAGR) of 8.1% from 2020 to 2027.

The primary driver behind the expansion of the GMP cytokines market is the increasing acceptance of cytokines in therapies for cancer and autoimmune diseases, as well as their potential role in stem cell therapy. However, the high costs associated with GMP cytokine therapies may hinder market growth.

Globally, stem cell research has gained significant attention as a means to enhance human health. Stem cells are crucial for the repair and regeneration of damaged tissues. Extensive studies have led many researchers to propose that these cells could pave the way for innovative treatments for various chronic conditions, including cardiovascular diseases and cancers. With advancements in technology and research, cytokine growth factors are also playing a vital role in the application of stem cells for new therapeutic approaches.

Hematopoietic stem cell therapy relies heavily on cytokines (growth factors) that regulate several critical aspects of hematopoietic stem cells, including self-renewal, quiescence, apoptosis, differentiation, and mobilization. Additionally, these growth factors facilitate the cooperative actions of various other growth factors and hormones that bind to receptors on these cells. Currently, hematopoietic stem cells are utilized in the treatment of over 80 medical conditions, encompassing immune system disorders, blood disorders, metabolic issues, neurological conditions, genetic disorders, and multiple cancer types, such as leukemia and lymphoma.

The increasing number of product launches in the realm of stem cell therapies is further propelling market growth. For example, in December 2019, CEVEC and CellGenix announced the launch of GMP TGF-?1 aimed at the cell and gene therapy sector. Such product introductions are expected to significantly enhance the growth of the GMP cytokines market throughout the forecast period.

The GMP cytokines market is categorized by type into TNF, interleukins, growth factors, and others. In 2019, the growth factors segment commanded the largest market share, driven by the high demand for cell culture-based research across various medical fields, including wound management, oncology, and cardiovascular studies. A notable study titled "Advances in Surgical Applications of Growth Factors for Wound Healing" was published in April 2019 by researchers at Shimane University Faculty of Medicine in Japan, highlighting the importance of growth factors in medical applications.

Furthermore, the GMP cytokines market is segmented by configuration into cell/gene therapy, tissue-engineered products, and others. The cell and gene therapy segment held the largest market share in 2019, while the tissue-engineered products segment is expected to exhibit the highest CAGR during the forecast period.

Key organizations such as the World Health Organization, National Health Service, Centers for Disease Control and Prevention, King Abdullah International Medical Research Center, and the Japanese Society of Molecular Cell Biology of Macrophages, along with various company websites, have been instrumental as primary and secondary sources in the preparation of this report.